Braftide

Overview

Braftide is an allosteric inhibitor for BRAF kinase by targeting the dimer interface of BRAF kinase and inhibiting the formation of BRAF dimers. Braftide inhibits wild-type BRAF and oncogenic BRAF G469A with IC 50 of 364 nM and 172 nM, respectively. Braftide inhibits MAPK signaling pathway, inhibits proliferation of KRAS mutant tumor cells ( EC 50 is 7.1 and 6.6 μM, for HCT116 and HCT-15), in combination of TAT sequence. Braftide can be used for cancer research.

Application

Products | Products > Peptides | Products > Disease Areas > Liver Cancer | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Obesity | Products > Disease Areas > Cancer | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Raf

Product Information

• Catalog No.: HY-P10436
• CAS No.: 2411851-64-2
• Molecular Formula: C57H94N16O13S
• Molecular Weight: 1243.52
• Purity: 99.51%
• Storage: Sealed storage, away from moisture. Powder -80°C, 2 years , -20°C, 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
• Availability: In-stock

Source

Original product source